Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. For more information please visit...

RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

Institutet, a world leader in cell therapy research. Its lead program, BT-101, is a novel MSC-based therapy with high bone-forming capability. Preclinical and clinical studies have demonstrated promising results, including improved bone formation,...

Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

a track record of advancing antibody drug conjugates (ADCs), T-cell engagers, and other next-generation therapeutic platforms from concept to clinical evaluation. “Chad has repeatedly demonstrated an ability to take bold scientific concepts and...

In Europe, Samsung Bioepis begins the commercialization of BYOOVIZ®, a biosimilar to Lucentis (Ranibizumab)

areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com

Peer-reviewed validation of a 60-channel closed-loop neurostimulation brain implant is published by Nia Therapeutics

Preclinical Validation in Freely Moving Large Animals In a chronic study of three sheep, the SNS demonstrated stable performance across core functions: Neural-state decoding. Machine-learning classifiers distinguished movement from stillness with...

Matisse Pharmaceuticals receives INN for M6229, recognizing it as a first-in-class drug, isupartob sodium

sepsis is the most common cause of in-hospital deaths, costing over $62 billion annually in the USA alone. For more information please visit, www.sepsis.com

Sapio Sciences Collaborates with the Wellcome Sanger Institute on Transforming Digital Laboratories

Sapio Sciences, the science-awareTM AI lab informatics platform, announced that the Wellcome Sanger Institute has selected the Sapio Informatics Platform as its central LIMS to underpin the Institute’s ambitious lab transformation program. The...

Medra Raises $52 Million in Series A Funding to Build Physical AI Scientists

Medra, the company developing the first platform for Physical AI Scientists, announced a $52 million Series A financing led by Human Capital, with participation from existing investors Lux Capital, Neo, and NFDG, alongside new investors Catalio...

Voranigo® (vorasidenib) from Servier has received multiple regional Prix Galien Awards

Kingdom, in Japan and Europe (27 countries of the European Union as well as Iceland, Liechtenstein and Norway). For more information please visit, www.servier.com

FIZE Medical, in an exclusive deal with Asahi Kasei Medical, has launched the FIZE kUO® System in Japan

global expansion and reinforces its mission to bring real-time kidney data into clinical decision-making. By transforming urine output into a continuously measured and analysed digital parameter, FIZE enables clinicians to better assess kidney...

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

Agostino Gemelli in Rome, clinical experience is rapidly expanding across Europe. With around 80 procedures performed within a short timeframe in eight countries, MOVIVA® is helping to establish a new era of endoscopic bariatric treatment –...

Health Canada has granted Celltrion approval for Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg).

Canada has approved Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all indications approved for Eylea. “Today’s approval lays a solid foundation for Celltrion’s expansion...

Samsung Bioepis Announces the Launch of Denosumab Biosimilars, OBODENCE™ and XBRYK™, in Europe

denosumab-containing medicinal products Hypercalcaemia in paediatric patients These highlights do not include all the information needed to use OBODENCE safely and effectively. Refer to the Summary of Product Characteristics for OBODENCE’s full...

Menarini Group Shares New Data on ELZONRIS® (tagraxofusp-erzs)

and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, announced that the company will present new data related to ELZONRIS®...

Eisai Completes FDA Submission for LEQEMBI® IQLIK™ Subcutaneous Starting Dose.

entire treatment journey. The injection time for each LEQEMBI IQLIK autoinjector takes approximately 15 seconds. The SC formulation also has the potential to reduce healthcare resources associated with IV dosing, such as preparation for infusion...

VahatiCor Closes Oversubscribed Series B Financing to Speed Up A-FLUX® Development for Coronary Microvascular Dysfunction

VahatiCor, a medtech company transforming cardiac care for Coronary Microvascular Dysfunction (CMD), announced the successful closing of its $23 million Series B financing led by S3 Ventures, with support from Intuitive Ventures, and a strategic...

FDA Approves Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) for Reducing Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).

injection once every three months. REDEMPLO utilizes the proprietary and differentiated Targeted RNAi Molecule (TRiM™) platform and is Arrowhead’s first FDA-approved medicine, marking a major milestone for the company as it transitions into...

Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

Emulate Brain-Chip R1. This first-in-class isogenic model of the neurovascular unit offers researchers a powerful new platform for studying drug transport across the blood-brain barrier (BBB) and investigating mechanisms of neuroinflammation. The...

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

clinical and preclinical research evaluating Modeyso™ (dordaviprone), as well as new preclinical data featuring JZP3507 (formerly ONC206) in central nervous system (CNS) tumors, reflecting Jazz's growing impact and innovation in neuro-oncology. Key...

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

What are the possible side effects of TREMFYA®? TREMFYA® may cause serious side effects. See "What is the most important information I should know about TREMFYA®?" The most common side effects of TREMFYA® include: respiratory tract infections,...